Summary of clinical efficacy studies of obeticholic acid (Obeticholic) in the treatment of liver fibrosis

Obeticholic Acid (OCA) is a selective farnesoid X receptor (FXR) agonist, which is widely used in the treatment of liver diseases such as primary biliary cholangitis (PBC) and liver fibrosis. FXR plays a key role in regulating bile acid metabolism, liver inflammatory response and fibrosis. Obeticholic acid inhibits liver inflammation and collagen deposition by activating the FXR signaling pathway, thereby slowing down the progression of liver fibrosis.

Multiple clinical studies have shown that obeticholic acid shows good therapeutic effects in patients with liver fibrosis. In a key Phase III clinical trial (REGENERATE study), obeticholic acid significantly improved the degree of liver fibrosis in patients with non-alcoholic steatohepatitis (NASH). Some patients had their fibrosis stage reversed and liver inflammation indicators also decreased. This result suggests that obeticholic acid has the potential to become an important drug for anti-fibrosis treatment.

Obeticholic acid is also outstanding in improving liver function and reducing liver inflammation. Research shows that it can effectively reduce liver enzyme (ALT, AST) levels and bilirubin content, reducing the burden on the liver. In addition, obeticholic acid has good safety and tolerability. Common side effects include mild itching and changes in lipid metabolism, but most of them can be controlled by adjusting the dose or supplementing with symptomatic treatment.

In summary, obeticholic acid, as one of the first approved FXR agonists, has demonstrated significant clinical value in the treatment of liver fibrosis and related liver diseases. In the future, with the accumulation of more long-term follow-up and real-world data, obeticholic acid is expected to play a broader role in the prevention and treatment of liver fibrosis, bringing better treatment options and improved quality of life to patients.

Reference materials:https://www.drugs.com/